PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-12.38%
Negative net income growth indicates shrinking profitability. Benjamin Graham would label it a concern unless explained by temporary factors.
-27.15%
Negative yoy D&A growth lowers the drag on net earnings. Benjamin Graham would confirm if it is due to fully depreciated assets or a slower expansion cycle.
-5631.45%
A negative yoy change in deferred tax might cut future liabilities. Benjamin Graham would verify whether real tax payments are simply being recognized sooner.
0.93%
SBC up to 10% yoy – Acceptable. Seth Klarman would expect net income to grow enough to offset the mild dilution.
-32.67%
A negative yoy change in working capital can free up cash. Benjamin Graham would confirm it is not from falling demand or asset disposal.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
107.56%
AP above 30% yoy – High. Philip Fisher would suspect possible cash strain or very aggressive use of supplier credit.
-665.24%
A negative yoy shift in other WC might free up cash flow. Benjamin Graham would confirm the items are not essential to operations or revenue generation.
5631.45%
Above 30% yoy – Major jump. Philip Fisher would investigate whether this is a recurring or truly one-time distortion.
-36.10%
Negative yoy CFO growth indicates a decline in core cash generation. Benjamin Graham would treat it as a serious warning unless cyclical factors explain it.
78.08%
CapEx above 15% yoy – Significant. Philip Fisher would demand strong evidence of high-ROI projects to offset the spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.08%
Above 15% yoy – Heavy. Philip Fisher would require evidence these invests drive future returns and do not hamper free cash flow too much.
66.67%
Debt repayment growth above 20% yoy – Strong deleveraging. Warren Buffett would see improved balance sheet health unless expansions are starved.
210.14%
Issuance above 15% yoy – Significant equity raise. Philip Fisher would require a very compelling reason to risk heavy shareholder dilution.
No Data
No Data available this quarter, please select a different quarter.